DXR logo

DAXOR CORP

DXRNASDAQ
🏆 #4322 by market capEarnings Mar 10US Equity
$11.70▲ $0.36 (+3.08%)
🌙 After hours$11.55▼ 1.28%Regular close · extended-hours price shown
🔔
Track DXR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.1%
7d▲ 4.9%
14d▲ 5.1%
30d▲ 21.7%
ytd▼ 0.7%
1y▼ 6.0%
🏦Market Cap
$68M
Small Cap
📈Revenue Growth (YoY)
-76.4%
Declining
📊Gross Margin
-106.5%
Thin
💵FCF Margin
-1811.4%
Thin
⚖️P/S Ratio
427.9x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$11.55 – $11.89
52-Week Range
$8.56 – $14.76
Volume
$3.86B
Avg Volume
$4.34B
Shares Outstanding
5.8M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$503,424
Last Q Revenue
$23,020
P/E Ratio
9.2
P/S Ratio
427.9x
EPS (TTM)
$1.25
Dividend Yield
0.00%
Dilution (1yr)
+2.5%

Why Investors Own DXR

  • ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DXR logo

DAXOR CORP

DXR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$503K▼ −76.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
37.5%▼ −62.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$9M▲ +1378.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$604K▼ −2452.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.1M▲ +2.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$112K▲ +$618K YoY
StockOtter · stockotter.space

About DAXOR CORP

Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$14.83
▲ +26.8% Upside
High Target$16.85
Low Target$13.69
Based on 28 analysts

Latest News & Updates

GlobeNewsWire·21d ago

Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in La

GlobeNewsWire·28d ago

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareho

Globe News Wire·Jul 29

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader

GlobeNewsWire·Jul 7

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in